Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
© Tashkin and Fabbri; licensee BioMed Central Ltd. 2010
Received: 17 May 2010
Accepted: 29 October 2010
Published: 29 October 2010
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting β2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limitation, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clinically meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated.
Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD. A LABA with a 24-hour duration of action could provide improvements in efficacy, compared with twice-daily LABAs, and the once-daily dosing regimen could help improve compliance. It is also desirable that a new LABA should demonstrate fast onset of action, and a safety profile at least comparable to existing LABAs.
A number of novel LABAs with once-daily profiles are in development which may be judged against these criteria. Indacaterol, a LABA with a 24-hour duration of bronchodilation and fast onset of action, is the most advanced of these. Preliminary results from large clinical trials suggest indacaterol improves lung function compared with placebo and other long-acting bronchodilators. Other LABAs with a 24-hour duration of bronchodilation include carmoterol, vilanterol trifenatate and oldaterol, with early results indicating potential for once-daily dosing in humans.
The introduction of once-daily LABAs also provides the opportunity to develop combination inhalers of two or more classes of once-daily long-acting bronchodilators, which may be advantageous for COPD patients through simplification of treatment regimens as well as improvements in efficacy. Once-daily LABAs used both alone and in combination with long-acting muscarinic antagonists represent a promising advance in the treatment of COPD, and are likely to further improve outcomes for patients.
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by increasing airflow limitation and respiratory symptoms, often associated with chronic comorbidities, leading to a significant burden for the patient.
Specific pharmacological therapy for COPD helps to prevent and control symptoms, reduce the frequency and severity of exacerbations, improve health status and improve exercise tolerance [1–3]. Inhaled bronchodilators, such as β2-agonists and muscarinic antagonists, improve lung function by altering airway smooth muscle tone but also act on peripheral airways . They reduce air trapping and improve emptying of the lungs, thereby reducing lung volumes, improving symptoms such as breathlessness and increasing exercise capacity [1, 5].
The present review focuses on the role and future of long-acting β2-agonists (LABAs) in the management of COPD, updating previously published reviews .
SABAs and LABAs commonly used in COPD
Dose delivered by inhaler (μg)
Duration of action (hours)
Onset of action
100, 200 (MDI & DPI)
Solution for nebulizer; oral (syrup, tablets); vials for injection
200 μg up to 4 times daily
400, 500 (DPI)
500 μg up to 4 times daily
4.5-12 (MDI & DPI)
Solution for nebulizer (20 μg/2 mL)
12 μg twice daily (Aerolizer/Easyhaler
9 μg† twice daily (Turbuhaler)
20 μg twice daily (Nebulizer)
Solution for nebulizer (15 μg/2 mL)
15 μg twice daily
25-50 (MDI & DPI)
50 μg twice daily
Current position in management guidelines
SABAs such as salbutamol (albuterol), terbutaline, pirbuterol or fenoterol and/or short-acting muscarinic antagonists (SAMAs) such as ipratropium bromide or oxitropium bromide are recommended as rescue medication for all severities of COPD to relieve acute symptoms of bronchospasm. For patients with Stage II (moderate) or more severe COPD, regular treatment with a twice-daily LABA such as formoterol or salmeterol, or a long-acting muscarinic antagonist (LAMA) such as tiotropium, is more effective and convenient than treatment with the shorter-acting agents . As symptoms progress, combining bronchodilators from different classes is recommended to improve efficacy. Inhaled corticosteroids may be added to bronchodilator treatment in patients with severe COPD and a history of repeated exacerbations.
No one long-acting bronchodilator is recommended over another in management guidelines , because few studies have specifically compared different LABAs [19, 20]. In addition, studies comparing LABAs with LAMAs have not been designed or powered to answer this clinical question to date, providing inconclusive results [21–23]. The choice therefore depends on availability and the response of the individual patient . Inhaled therapy is preferred to oral therapy, in light of the greater risk of systemic side effects with oral beta-agonists and the unfavorable safety profile of oral methylxanthines.
Recently, there has been extensive research into the efficacy and safety of available twice-daily LABAs, as well as the development of new long-acting β2-agonists which have the potential for once-daily use . This paper focuses on the current and future role of LABAs in COPD management. The efficacy and safety of currently available LABAs is reviewed, and their limitations considered. Articles were identified using a PubMed search including search terms for all currently available LABAs (salmeterol, formoterol, arformoterol), β2-agonists, efficacy, safety and chronic obstructive pulmonary disease/COPD. This is followed by the authors' views on the ideal criteria for a new LABA for COPD, and a discussion of the extent to which novel LABAs, currently being developed, may meet these criteria.
Summary of clinical efficacy for currently available β2-agonists in COPD
Improvement in outcome
Duration of action (hours)1
Quality of life
Improvements in pre-bronchodilator forced expiratory volume in 1 second (FEV1) ranged from 50-90 mL compared with placebo [26, 30, 36, 40, 49]. Bronchodilation was rapid in onset with formoterol , although salmeterol had an onset of action slower than salbutamol or ipratropium bromide .
Improvements in lung function were sustained in studies of 3 months to 3 years' duration when twice-daily LABAs were used as maintenance therapy [28–31, 46, 48, 51, 52]. Some studies have suggested there may be a decline in bronchodilator efficacy over time with salmeterol [53, 54]; over 6 months, significant declines in peak forced vital capacity (FVC) relative to placebo (-83 mL, p < 0.05), but not FEV1 (-12 mL), were observed with salmeterol . Other studies have also suggested a partial loss of bronchodilator efficacy of formoterol over time. For example, the initial improvement in mean trough FEV1 (95% confidence interval [CI]) with formoterol 12 μg compared with placebo declined from 110 ml (90-130) after Day 1 to 70 mL (40-100) at Week 12 and to 50 ml (10-90) at Week 52 . Moreover, there appears to be a partial decline in the integrated 12-hour improvement in FEV1 following the morning dose of formoterol 24 μg from 3 to 12 months of twice-daily therapy . However, no evidence of clinically meaningful tolerance has been demonstrated in pooled or meta-analyses of salmeterol [56, 57].
Further, in a post-hoc analysis from the 3-year Towards a Revolution in COPD Health (TORCH) study, salmeterol reduced the rate of decline in lung function by 13 mL/year compared with placebo (p = 0.003), which was not statistically different from the reduction in the rate of decline by salmeterol in combination with the inhaled corticosteroid fluticasone propionate .
Formoterol and salmeterol have demonstrated similar or greater improvements in lung function compared with ipratropium bromide [26, 29, 39, 44, 45] and significantly greater improvements compared with theophylline [35, 46, 59], but appear to be less effective than tiotropium [21, 60].
Numerous tools and questionnaires have been developed to assess respiratory symptoms in COPD ranging from patient rating of symptoms on diary cards, to validated scales such as the Transition Dyspnea Index (TDI) and Borg scale of perceived dyspnea, for which minimal clinically important differences (MCID) have been established [61–63].
Both formoterol and salmeterol have demonstrated significant improvement compared with placebo in diary card symptom scores including breathlessness, together with significant reductions in the requirement for rescue medication [12, 23, 27, 29, 30, 32, 36, 37, 40, 48, 50, 51]. Improvements in symptoms were generally similar [26, 27, 46] or greater [29, 59] with formoterol and salmeterol than with ipratropium bromide and theophylline.
Fewer studies have included the TDI instrument, and these have yielded inconsistent results [21, 26, 32, 33, 40, 43]. Formoterol 18 μg twice daily, but not 4.5 μg or 9 μg twice daily via the Turbuhaler, significantly improved TDI by 1.15 units compared with placebo (1.77 vs 0.62 units; p = 0.002) , achieving the MCID (≥1 unit) for this instrument. Similarly, nebulized arformoterol (the active (R,R)-enantiomer of formoterol) 25 μg and 50 μg but not 15 μg twice daily significantly improved TDI (1.08 and 1.04 units vs placebo respectively) . In contrast, salmeterol has not achieved the MCID for TDI in clinical studies [21, 26, 33, 40, 43]. Donohue et al  found that only 35% of patients receiving salmeterol achieved the MCID (p = ns vs placebo), compared with 42% receiving the LAMA tiotropium (p < 0.01 vs placebo).
There are fewer studies investigating the effect of LABAs on exercise tolerance. Two 12-week studies found no significant difference in distance covered in the incremental shuttle walking test with formoterol 18 μg twice daily via Turbuhaler compared with placebo [32, 51]. Similarly, studies with salmeterol show inconsistent effects on walking tests compared with placebo [12, 39, 42, 64]. However, in constant (submaximal) work rate exercise endurance tests (considered to be more responsive to the effect of pharmacotherapy) , significant improvements in exercise tolerance have been demonstrated for formoterol and salmeterol, accompanied by improvements in dynamic hyperinflation (exercise-induced air trapping which is a significant contributor to exercise limitation due to intolerable dyspnea) [65, 66]. For example, in cycle tests performed at 75% of peak work rate, salmeterol significantly prolonged exercise time compared with placebo (6.0 ± 0.8 vs 4.5 ± 0.8 minutes, p < 0.05), although this fell just short of the 1.75 minute MCID proposed by Casaburi .
Data with active comparators are limited, but small studies have found similar improvements in exercise endurance and dyspnea ratings during submaximal or progressive exercise tests between twice-daily LABAs and ipratropium bromide [68–70].
Health-related quality of life
In the majority of studies, significant improvements in health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) have been demonstrated with formoterol compared with placebo [23, 29–31, 46] and with salmeterol compared with placebo [33, 36, 48, 71] although other studies have failed to demonstrate a significant effect on quality of life [21, 40, 43, 51].
In some [29, 30, 48, 71], but not all [23, 28, 31, 33, 36] studies, improvements compared with placebo exceeded the MCID of 4 units for the SGRQ . Although improvements in health-related quality of life with formoterol and salmeterol were at least as good as those with ipratropium bromide [26, 27, 29] and theophylline , overall, a meta-analysis found that LABAs produced a mean change from baseline of 3.36 units in SGRQ , falling short of the MCID for this instrument. Similarly, in a responder analysis of a 6-month study, only 42% of patients receiving salmeterol achieved the MCID for health-related quality of life, compared with 40% for placebo (p = ns) and 51% receiving tiotropium (p < 0.05 vs salmeterol) .
Exacerbations contribute greatly to the increased morbidity and diminished health-related quality of life of COPD patients . However, there has been a lack of a consistent and widely accepted definition with which to evaluate and compare the efficacy of therapeutic interventions on this outcome . Definitions of, and methods for counting, COPD exacerbations vary across studies, and statisticians disagree as to the most appropriate statistical method for analysis [76, 77]. Thus, the results of clinical studies must be interpreted with caution.
To date, clinical studies have not been specifically designed to investigate the effect of formoterol on exacerbations, and no significant benefit on moderate to severe exacerbations has been demonstrated [23, 30, 31, 78]. Salmeterol has more consistently demonstrated a significant effect on COPD exacerbation rate, which may reflect the study designs used . The 3-year TORCH study found that salmeterol monotherapy reduced the annual rate of COPD exacerbations (requiring oral corticosteroids and/or antibiotics and/or hospitalization) by 15% compared with placebo (p < 0.001), although the greatest reductions were observed in the combination salmeterol/fluticasone propionate arm (25% annual reduction compared with placebo, p < 0.001) .
In a meta-analysis of 14 randomized clinical trials involving more than 6,400 patients, LABAs (salmeterol or formoterol) significantly reduced exacerbations requiring study withdrawal or hospitalization compared with placebo, with a relative risk of 0.78 (95% CI, 0.67-0.91) . Hospitalizations tend to be relatively rare events and there may be large variability in the criteria applied by different physicians for hospitalizing a patient for an exacerbation, so this result is difficult to interpret. However, it is interesting to note that the use of ICS was not associated with a further risk reduction . In a more recent meta-analysis of 23 randomized controlled trials of twice-daily LABAs (16 salmeterol vs placebo, four formoterol vs placebo, three salmeterol vs tiotropium and one formoterol vs tiotropium), LABAs significantly reduced the risk of an exacerbation compared with placebo (odds ratio [OR] 0.84; 95% CI, 0.76-0.92), whereas tiotropium significantly reduced the exacerbation risk compared with a LABA (OR 0.82; 95% CI, 0.72-0.93) . A LABA-ICS combination tended to reduce the risk of an exacerbation more than a LABA alone, although this did not reach statistical significance (OR 0.90; 95% CI, 0.80-1.01).
In summary, evidence to date suggests that both formoterol and salmeterol provide significant improvements in lung function, symptoms including dyspnea, and health-related quality of life. However, for the latter two endpoints, not all patients appear to achieve clinically meaningful improvements, and improvements were lower than those achieved with the once-daily LAMA tiotropium. Studies using the sensitive measure of submaximal exercise testing suggest there is a beneficial effect on exercise tolerance, although data are limited in this area. There are few definitive studies investigating the effect of treatment on exacerbations and results should be interpreted with caution, but suggest a significant effect, at least for salmeterol.
Given the general trend for twice-daily LABAs to provide improved lung function and more consistent symptom control compared with shorter-acting comparators (Table 2), one could argue that a longer duration of action is desirable in COPD . The extension of this argument is that efficacy could be further improved by the introduction of a once-daily LABA.
There is clear consensus with regard to the central role of inhaled bronchodilators as the standard of care in COPD patients. However, recent concerns have been raised suggesting that LABA use could lead to an increased risk of respiratory death in patients with asthma. This was initiated by the results of the Salmeterol Multicenter Asthma Research Trial (SMART), which investigated the safety of adding salmeterol to usual asthma treatment in patients not already receiving a LABA; it was stopped following an interim analysis in 26,355 patients because of a small but significant increase in the number of asthma-related deaths in the salmeterol group . These results raised significant doubts about the safety of LABA monotherapy in patients with asthma. Recent editorials have recommended that physicians should continue to use LABAs to treat asthma, but only when combined with appropriate doses of inhaled corticosteroids [82, 83].
In COPD there are no restrictions on LABA use as monotherapy. COPD is a distinct disease from asthma, although there is some degree of overlap, with an estimated 10-50% of COPD patients having concomitant asthma. This wide variation in reported prevalence may relate to differences in diagnostic criteria [84, 85]. An overlap in symptoms, together with the lack of validated discriminatory biomarkers, can make differential diagnosis difficult. The major distinguishing features between the two diseases are clinical: in general, COPD occurs later in life, with slowly progressive symptoms during exercise and is associated with a history of smoking or exposure to noxious gases and particulates. Asthma is likely to present early in life (often in childhood) and be associated with symptoms which vary from day to day, often at night or in the early morning; subjects often have a history of asthma in their family and airflow limitation tends to be more reversible than in COPD [1, 86]. It is important to recognize that COPD, in most cases, is associated with significant, albeit never complete, reversibility [87–89] at one time or another. Therefore, it is not appropriate as is sometimes done, to refer to COPD patients who exhibit significant reversibility in response to a bronchodilator as having an 'asthmatic' component or 'mixed disease'. Indeed, the fact that most COPD patients respond significantly to a bronchodilator provides the major rationale for the recommendation of bronchodilators as the mainstay of therapy for COPD.
Effects of treatment with salmeterol and fluticasone on mortality
Salmeterol plus fluticasone (D)
No. of subjects
No. of deaths
Probability of deaths at 3 years (%)
Hazard ratio (95% confidence interval)
Clinical studies have demonstrated that both formoterol and salmeterol are well tolerated, over periods of at least a year [28, 30, 31, 36, 48, 78]. Commonly occurring LABA class effects include palpitations, headache and tremor, which may limit the dose that can be tolerated, especially in some older patients . Cardiovascular side effects are also possible in susceptible patients , and there is some risk associated with the use of β2-agonists in patients with COPD and concomitant cardiac diseases, particularly chronic heart failure [94, 95].
Chronic heart failure is a frequent comorbidity in patients with COPD. Cazzola et al  reported that COPD patients in Italy were at increased risk of chronic heart failure compared with the general population (7.9% compared with 2%), while in a Scottish study, 11.9% patients with COPD also had chronic heart failure . Older individuals were at even higher risk in both studies. Moreover, heart failure may be under-diagnosed in COPD due to diagnostic confusion between the two diseases . Research by Au et al. [99, 100] indicates a strong trend towards a dose-response relationship of increased hospitalization and death, due to heart failure in patients with underlying heart failure who received increasing amounts of β2-agonist. Thus it is important that physicians should exercise caution in using high doses of β2-agonists in such patients.
However, studies specifically investigating safety have demonstrated that formoterol and salmeterol have good cardiovascular safety profiles [101, 102]. Further, studies with formoterol found a similar profile irrespective of device or formulation [103, 104]. In a large cohort of patients with no or stable cardiac comorbidities, the proportion of patients with treatment-emergent atrial tachycardia ranged from 27%-32% and was non-significantly higher, by 2%-5% (p = 0.70), in patients receiving salmeterol or arformoterol compared with placebo; more serious arrhythmias did not increase, nor did mean heart rate .
Formoterol and salmeterol have acceptable benefit:risk profiles in the treatment of COPD; however, both have their limitations. For example, both formoterol and salmeterol have 12-hour durations of action and are approved for twice-daily dosing. The longer duration of bronchodilation of twice-daily LABAs compared with SABAs appears to be associated not only with improved lung function but also with more consistent efficacy in symptomatic endpoints, such as breathlessness and quality of life (Table 2). Evidence also indicates that LAMAs with a 24-hour duration of action have additional benefits in comparison with shorter acting SAMAs . This suggests that sustained bronchodilation is desirable for a bronchodilator  and that a LABA with a 24-hour duration of action could provide further improvements in efficacy compared with twice-daily LABAs. In addition, patient adherence to treatment plans is a major obstacle to successful COPD management, especially since it is likely that patients will also be on a range of medications for comorbidities. Simplified dosing regimens are known to improve compliance , so that once-daily dosing is an important strategy to improve compliance and is a regimen preferred by most patients .
Fast onset of action is a significant feature of bronchodilators and may be beneficial for patients with COPD. Rapid relief of symptoms which patients can feel from the first dose provides reassurance of effect, and is likely to improve compliance with the medication [108, 109]. When administered in the morning, the fast onset of action of bronchodilators is also advantageous, since COPD symptoms and patients' ability to perform daily activities appear to be worst in the morning . While formoterol has an onset of action similar to salbutamol, salmeterol may not produce a significant increase in bronchodilation for as long as 2 hours following the dose.
For COPD patients, bronchodilator medication is a chronic maintenance therapy, and it is desirable that efficacy should be maintained over time. As discussed above there is some evidence of loss of bronchodilator effectiveness over time with β2-agonists, as demonstrated by Tsagaraki et al. , Donohue et al. , Dahl et al.  and Rossi et al.  although the clinical significance of these changes remains unclear.
Studies to date with twice-daily LABAs indicate that a minority of patients achieve clinically relevant improvements in dyspnea or health-related quality of life, based on current validated thresholds [21, 73]. Data with current twice-daily LABAs in terms of preventing COPD exacerbations are mixed, with some studies showing no effect [30, 31, 48]. However, evidence from large datasets such as TORCH and pooled analyses reviewed above support a relatively modest reduction in the rate of moderate and severe exacerbations [28, 73, 79].
Improvements in these areas are desirable, but it is also essential that a new LABA has a comparable, if not better, safety profile compared with twice-daily LABAs. LABAs are associated with known class effects, the most significant being related to cardiac safety . While the balance of evidence (as reviewed above) indicates that current LABAs are well tolerated, it is important that any new entry to the market ensures that potential cardiac effects are minimized, especially taking into account that COPD patients are often older and may have cardiovascular comorbidities.
Finally, consideration should be given to the delivery of any new molecule, ensuring the inhaler device is appropriate to the COPD patient. Many COPD patients have difficulty in using metered-dose inhalers so dry powder inhalers that are of low resistance, relatively insensitive to changes in airflow and can be used irrespective of inspiratory flow rate may be beneficial . Soft-mist inhalers are also less technique-dependent than metered-dose inhalers , and may hold promise for future delivery of LABAs alone or in combination with other agents.
Ultra-LABAs in development for use in COPD
'Ultra-LABA' is a term already in use to describe the class of once-daily LABAs in development [6, 113]. Ultra-LABAs providing not only once-daily dosing but also improvements in the range of criteria outlined above would represent an advance on currently available LABAs, and an alternative to existing once-daily bronchodilators for the treatment of COPD. Tiotropium, the only once-daily inhaled bronchodilator currently available, is a LAMA that significantly improves lung function, increases exercise capacity and improves effectiveness of pulmonary rehabilitation, improves health status, and reduces exacerbations [1, 79]. Although a four-year study of tiotropium on a background of usual therapy did not reduce the rate of decline in lung function , post-hoc analyses did demonstrate a modest, but significant, reduction in the rate of decline in lung function with tiotropium compared with placebo in patients not on other maintenance drugs [114, 115]. However, tiotropium is relatively slow in onset of action and is associated with anticholinergic side effects, such as dry mouth (most commonly) and urinary retention (rarely) .
Ultimately, the choice of one agent over another as monotherapy in individual COPD patients will depend on a number of factors, including the expected side effects of each class of drugs, data on comparative efficacy with respect to onset, magnitude and duration of action, preference for the delivery device used and cost.
A number of novel LABAs with once-daily profiles are in development . Here, we summarize the data available to date for the most promising of these.
It has been hypothesized that indacaterol's long duration of action may relate to its high affinity for the lipid raft domain of the cell membrane  (cholesterol-enriched microdomains of the lipid membrane, where β2-receptors are held together in close contact with signaling molecules and effectors) .
A number of placebo- and active-controlled Phase III studies in COPD have been completed or are ongoing [55, 124–129]. Indacaterol 150 μg once daily significantly improved trough FEV1 at 12 weeks by 130-180 mL compared with placebo (p < 0.001) [125, 127–129] while the 300 μg dose provided improvements of 170-180 mL (p < 0.001) [55, 127, 129], sustained over 1 year [55, 129]. Both doses were significantly more effective than open-label tiotropium (p ≤ 0.01)  while in further studies, the 150 μg dose was significantly more effective than salmeterol 50 μg twice daily (p < 0.001) , and the 300 μg dose was significantly more effective than formoterol 12 μg twice daily (p < 0.05) .
Patient outcomes were also improved: indacaterol 150 and 300 μg significantly improved dyspnea as measured by TDI to a clinically relevant degree in a six month study (≥1 unit, p < 0.001)  with similar results achieved for indacaterol 300 μg throughout a 12 month study (1.00-1.32 unit improvement vs placebo, p < 0.001) . In addition, indacaterol 150 and 300 μg were found to be at least as effective as open-label tiotropium in improving clinical outcomes over a 26-week period . Indacaterol 150 and 300 μg also significantly reduced dyspnea compared with salmeterol and formoterol (p < 0.05) [55, 128], and significantly reduced rescue medication use compared with tiotropium and salmeterol (p < 0.05) [127, 128]. Patients reported significant improvements in health-related quality of life as measured by SGRQ for both doses compared with placebo in 6 month studies (p ≤ 0.01) [127, 128] with the 150 μg dose achieving a clinically relevant improvement of 5 units versus placebo at 26 weeks in one study (p < 0.001) . Further, indacaterol 300 μg achieved significant, clinically relevant improvements over one year (-4.7 units improvement at Week 52, p < 0.001 vs placebo) . In studies of up to one year, indacaterol was well tolerated with an acceptable safety profile, including cardiovascular safety, similar to placebo, and comparable to tiotropium and formoterol [55, 127, 128].
Olodaterol (BI-1744 CL) is in a late stage of development. Preclinical studies with olodaterol suggested a potential for once-daily dosing in humans, along with a rapid onset of action and a favorable safety profile [130, 131]. Phase III studies are based on doses of 5 and 10 μg once daily, delivered via the Respimat® device .
Carmoterol has demonstrated long duration of activity in patients with COPD [132, 133], with no tolerance observed over two weeks of treatment . In a Phase II study, the 2 μg and 4 μg doses of carmoterol given once daily resulted in significant bronchodilation over 24 hours compared to placebo and comparable to that obtained with salmeterol 50 μg twice daily in patients with COPD . No cardiac safety concerns were reported at doses less than 16 μg in healthy volunteers , while in patients with COPD initial data also suggests it has a good safety profile and is well tolerated .
Vilanterol trifenatate (GW642444M) [138, 139] has also completed Phase II clinical trials [4, 124]. In a four-week dose-ranging study involving 605 subjects, all doses (3, 6.25, 12.5, 25 and 50 μg once daily) achieved statistically significant increases in lung function (trough FEV1) compared to placebo (p < 0.05), with the two highest doses exceeding a predefined threshold of 130 mL increase in FEV1. Improvements in lung function were sustained over 24 hours. Vilanterol trifenatate was well tolerated at all doses and the frequency of adverse events was comparable to placebo .
PF-00610355 has been investigated in Phase I studies in healthy male subjects. A single dose of PF-00610355 450 μg had a superior duration of action as measured by specific airway conductance (sGAW) compared with placebo (16.4 hours longer) and salmeterol (9.8 hours longer) . PF-00610355 was also well tolerated over 14 days within the anticipated clinical dose range (≤600 μg) . Further studies will be needed to confirm if this drug has a 24-hour duration of bronchodilator action and is suitable for once-daily dosing.
Potential impact of ultra-LABAs on COPD management as monotherapy and in combination
It could be hypothesized that a longer duration of bronchodilation with an ultra-LABA may be associated with superior and more consistent efficacy over a range of endpoints than is achieved with a twice-daily LABA. Furthermore, compared with complicated or multiple treatment regimens, simplified (once-daily) treatment regimens represent a significant convenience benefit and increase the likelihood of compliance with treatment - as does fast onset of action and a favorable safety profile. Together, these benefits could lead to improved overall clinical outcomes in COPD patients , and might help compliance with GOLD guidelines.
Based on the results of studies combining currently available LABAs and LAMAs [23, 50, 142–145], significantly greater improvements in lung function and symptoms can be achieved with a twice-daily LABA in combination with a LAMA compared with tiotropium used alone. Further, initial data from a single study suggests LABA/LAMA combinations may provide superior bronchodilator efficacy compared with LABA/ICS, at least in moderate COPD ; however, this was a short-term (6 weeks) study and did not assess possible differences in patient-reported outcomes. Longer-term studies are required with sufficient power to assess the relative efficacy of such combinations on quality of life and exacerbations. The introduction of ultra-LABAs is likely to further improve outcomes for patients, when used in combination with a LAMA. Current opinion is that it will be advantageous to develop inhalers containing combinations of two or more classes of once-daily long-acting bronchodilator drugs, in an attempt to simplify treatment regimens as much as possible . Several ultra-LABA/LAMA combinations are in development, including QVA149 (indacaterol + NVA237 [glycopyrrolate]) [147, 148] and vilanterol trifenatate/darotropium bromide .
As COPD progresses, patients with frequent exacerbations may require 'triple therapy' with a LAMA, LABA and an ICS. Evidence to date indicates that ICS/LABA in combination with tiotropium improves lung function, symptoms and health status, and reduces the risk of hospitalizations compared with tiotropium alone in patients with COPD [149–151]. These findings lend support to the concept that combining different classes of drugs with different mechanisms such as ultra-LABAs and once-daily LAMAs and ICS will further improve efficacy, and represent an important step towards the goal of optimal control for COPD patients.
Long-acting bronchodilators are fundamental to the management of COPD; however, many patients remain symptomatic despite their use. Twice-daily LABAs salmeterol and formoterol provide some improvements in clinical outcomes compared with placebo and, although there are known class effects, have a favorable safety profile. However, in studies including validated instruments to measure dyspnea and health-related quality of life, not all patients achieve clinically meaningful improvements.
Thus, there is still an unmet need, particularly to improve symptoms, in many COPD patients. A range of features can be identified that could be considered to be criteria for a new LABA to fulfil. In particular, longer duration of action than 12 hours appears to be associated with improved, more consistent benefits across a range of outcomes. New ultra-LABAs have the potential to improve outcomes for COPD patients, both alone (providing an alternative to the only once-daily muscarinic antagonist bronchodilator currently available) or in combination. There are already promising data for indacaterol, which is likely to be the first ultra-LABA to be available for the treatment of COPD.
DPT - David Geffen School of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA, Los Angeles, California, USA; LMF Section of Respiratory Diseases, Department of Oncology, Haematology and Respiratory Diseases, University of Modena & Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, I-41124 Modena, Italy.
List of abbreviations used
Cyclic Adenosine Monophosphate
Chronic Obstructive Pulmonary Disease
Dry Powder Inhaler
Forced Expiratory Volume in one second
Forced Vital Capacity
Global initiative for Chronic Obstructive Lung Disease
Long-acting Muscarinic Antagonists
Minimal Clinically Important Difference
Short-acting Muscarinic Antagonist
Specific Airway Conductance
Salmeterol Multicentre Asthma Research Trial
St. George's Respiratory Questionnaire
Transition Dyspnea Index
Towards a Revolution in COPD Health.
We thank Mary Sayers of ACUMED who provided medical writing services. This support was funded by Novartis Pharma AG.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009Google Scholar
- National Institute for Health and Clinical Excellence: Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. 2010, National Clinical Guideline Centre, Accessed June 28, 2010, [http://guidance.nice.org.uk/CG101/Guidance/pdf/English]Google Scholar
- Niewoehner DE: Clinical practice. Outpatient management of severe COPD. N Engl J Med. 2010, 362: 1407-16. 10.1056/NEJMcp0912556.PubMedGoogle Scholar
- Hasegawa M, Makita H, Nasuhara Y, Odajima N, Nagai K, Ito Y, Betsuyaku T, Nishimura M: Relationship between improved airflow limitation and changes in airway caliber induced by inhaled anticholinergics in chronic obstructive pulmonary disease. Thorax. 2009, 64: 332-8. 10.1136/thx.2008.103671.PubMedGoogle Scholar
- Cooper C: Airflow obstruction and exercise. Respir Med. 2009, 103: 325-34. 10.1016/j.rmed.2008.10.026.PubMedGoogle Scholar
- Cazzola M, Matera MG: Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008, 155: 291-9. 10.1038/bjp.2008.284.PubMedPubMed CentralGoogle Scholar
- Johnson M: The β2-adrenoceptor. Am J Respir Crit Care Med. 1998, 158: S146-53.PubMedGoogle Scholar
- Roux E, Molimard M, Savineau JP, Marthan R: Muscarinic stimulation of airway smooth muscle cells. Gen Pharmac. 1998, 31: 349-56. 10.1016/S0306-3623(98)00007-X.Google Scholar
- Rhoden KJ, Meldrum LA, Barnes PJ: Inhibition of cholinergic neurotransmission in human airways by β2-adrenergic receptors. J Appl Physiol. 1988, 65: 700-5.PubMedGoogle Scholar
- Brichetto L, Song P, Crimi E, Rehder K, Brusasco V: Modulation of cholinergic responsiveness through the β2-adrenergic receptor signal transmission pathway in bovine trachealis. J Appl Physiol. 2003, 95: 735-41.PubMedGoogle Scholar
- Shrewsbury S, Pyke S, Britton M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J. 2000, 320: 1368-73. 10.1136/bmj.320.7246.1368.Google Scholar
- Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997, 10: 815-21.PubMedGoogle Scholar
- Serevent Diskus: Prescribing information (US). 2008, GlaxoSmithKline, accessed March 24 2010, [http://www.fda.gov/drugs]Google Scholar
- Foradil Aerolizer: Prescribing information (US). 2006, Novartis, accessed March 24 2010, [http://www.fda.gov/drugs]Google Scholar
- Brovana: Prescribing information (US). 2007, Sepracor, accessed March 24 2010, [http://www.fda.gov/drugs]Google Scholar
- Perforomist: Prescribing information (US). 2007, Dey LP, accessed March 24 2010, [http://www.fda.gov/drugs]Google Scholar
- Ventolin Accuhaler: Summary of Product Characteristics. 2009, Allen & HanburysGoogle Scholar
- Bricanyl Turbohaler: Summary of Product Characteristics. 2009, Astra ZenecaGoogle Scholar
- Jara M, Lanes SF, Wentworth C, May C, Kesten S: Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf. 2007, 30: 1151-60. 10.2165/00002018-200730120-00007.PubMedGoogle Scholar
- Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP: Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008, 2: 37-48. 10.1177/1753465808089455.PubMedGoogle Scholar
- Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002, 122: 47-55. 10.1378/chest.122.1.47.PubMedGoogle Scholar
- Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M: A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008, 102: 1033-44. 10.1016/j.rmed.2008.02.001.PubMedGoogle Scholar
- Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J: Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008, 102: 1511-20. 10.1016/j.rmed.2008.07.020.PubMedGoogle Scholar
- van der Molen T, Pieters W, Bellamy D, Taylor R: Measuring the success of treatment for chronic obstructive pulmonary disease - patient, physician and healthcare payer perspectives. Respir Med. 2002, 96 (Suppl C): S17-S21. 10.1016/S0954-6111(02)80030-0.PubMedGoogle Scholar
- Celli BR, MacNee W, committee members: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23: 932-46. 10.1183/09031936.04.00014304.PubMedGoogle Scholar
- Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999, 115: 957-65. 10.1378/chest.115.4.957.PubMedGoogle Scholar
- Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K: Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 163: 1087-92.PubMedGoogle Scholar
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007, 356: 775-89. 10.1056/NEJMoa063070.PubMedGoogle Scholar
- Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G, the Formoterol in Chronic Obstructive Pulmonary Disease I Study Group: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 164: 778-84.PubMedGoogle Scholar
- Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003, 22: 912-9. 10.1183/09031936.03.00027003.PubMedGoogle Scholar
- Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003, 21: 74-81. 10.1183/09031936.03.00031402.PubMedGoogle Scholar
- Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002, 19: 936-43. 10.1183/09031936.02.00240902.PubMedGoogle Scholar
- Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007, 29: 261-78. 10.1016/j.clinthera.2007.02.009.PubMedGoogle Scholar
- Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med. 2001, 95: 817-21. 10.1053/rmed.2001.1161.PubMedGoogle Scholar
- Broseghini C, Testi R, Polese G, Tosatto R, Rossi A: A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2005, 18: 103-8. 10.1016/j.pupt.2004.10.006.PubMedGoogle Scholar
- Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, the TRial of Inhaled STeroids ANd long-acting beta2 agonists study group: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003, 361: 449-56. 10.1016/S0140-6736(03)12459-2.PubMedGoogle Scholar
- Chhabra SK, Vijayan VK, Vasu T: Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci. 2006, 48: 97-102.PubMedGoogle Scholar
- Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K, the Formoterol Study Group: Efficacy and safety of formoterol fumarate delivered by nebulisation to COPD patients. Respir Med. 2008, 102: 189-97. 10.1016/j.rmed.2007.10.007.PubMedGoogle Scholar
- Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP: Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax. 1996, 51: 689-93. 10.1136/thx.51.7.689.PubMedPubMed CentralGoogle Scholar
- Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T: The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003, 124: 834-43. 10.1378/chest.124.3.834.PubMedGoogle Scholar
- Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA: Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2008, 5: 25-34. 10.1080/15412550701816187.PubMedGoogle Scholar
- Kaushik ML, Kashyap S, Bansal SK, Sharma A: Effectiveness of salmeterol in stable COPD. Indian J Chest Dis Allied Sci. 1999, 41: 207-12.PubMedGoogle Scholar
- Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002, 166: 1084-91. 10.1164/rccm.2112055.PubMedGoogle Scholar
- Matera MG, Cazzola M, Vinciguerra A, Di Perna F, Calderaro F, Caputi M, Rossi F: A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1995, 8: 267-71. 10.1006/pulp.1995.1036.PubMedGoogle Scholar
- Minakata Y, Iijima H, Takahashi T, Miura M, Ogawa H, Kimura K, Koga T, Kinoshita M, Tsuda T, Aizawa H, Ichinose M: Efficacy and safety of formoterol in Japanese patients with COPD. Intern Med. 2008, 47: 217-23. 10.2169/internalmedicine.47.0494.PubMedGoogle Scholar
- Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G, the Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002, 121: 1058-69. 10.1378/chest.121.4.1058.PubMedGoogle Scholar
- Schultze-Werninghaus G: Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease. Lung. 1990, 168 (Suppl): 83-9. 10.1007/BF02718118.PubMedGoogle Scholar
- Stockley RA, Chopra N, Rice L: Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006, 61: 122-8. 10.1136/thx.2004.033266.PubMedPubMed CentralGoogle Scholar
- Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M: Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008, 68: 1975-2000. 10.2165/00003495-200868140-00004.PubMedGoogle Scholar
- van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000, 15: 878-85. 10.1034/j.1399-3003.2000.15e11.x.PubMedGoogle Scholar
- Wadbo M, Löfdahl CG, Larsson K, Skoogh BE, Tornling G, Arweström E, Bengtsson T, Ström K, Swedish Society of Respiratory Medicine: Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J. 2002, 20: 1138-46. 10.1183/09031936.02.00301702.PubMedGoogle Scholar
- Campbell M, Eliraz A, Johansson G, Tornling G, Nihlén U, Bengtsson T, Rabe KF: Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005, 99: 1511-20. 10.1016/j.rmed.2005.08.016.PubMedGoogle Scholar
- Donohue JF, Menjoge S, Kesten S: Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med. 2003, 97: 1014-20. 10.1016/S0954-6111(03)00131-8.PubMedGoogle Scholar
- Tsagaraki V, Amfilochiou A, Markantonis SL: Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract. 2006, 60: 415-21. 10.1111/j.1368-5031.2006.00849.x.PubMedGoogle Scholar
- Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, the INVOLVE (indacaterol: value in COPD pulmonary disease: longer term validation of efficacy and safety) study investigators: Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax. 2010, 65: 473-479. 10.1136/thx.2009.125435.PubMedGoogle Scholar
- Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K: The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005, 18: 19-22. 10.1016/j.pupt.2004.07.005.PubMedGoogle Scholar
- Stockley RA, Whitehead PJ, Williams MK: Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res. 2006, 7: 147-10.1186/1465-9921-7-147.PubMedPubMed CentralGoogle Scholar
- Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-8. 10.1164/rccm.200712-1869OC.PubMedGoogle Scholar
- Di Lorenzo G, Morici G, Drago A, Pellitteri ME, Mansueto P, Melluso M, Norrito F, Squassante L, Fasolo A: Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group. Clin Ther. 1998, 20: 1130-48. 10.1016/S0149-2918(98)80109-4.PubMedGoogle Scholar
- van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ: Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005, 26: 214-22. 10.1183/09031936.05.00140404.PubMedGoogle Scholar
- Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984, 85: 751-8. 10.1378/chest.85.6.751.PubMedGoogle Scholar
- Make B, Casaburi R, Kline Leidy N: Interpreting results from clinical trials: understanding minimal clinically important differences in COPD outcomes. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005, 2: 1-5. 10.1081/COPD-200051363.PubMedGoogle Scholar
- Witek TJ, Mahler DA: Meaningful effect size and patterns of response of the Transition Dyspnea Index. J Clin Epidemiol. 2003, 56: 248-55. 10.1016/S0895-4356(02)00589-9.PubMedGoogle Scholar
- Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, Donaldson N, Polkey MI, Moxham J: Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004, 59: 471-6. 10.1136/thx.2003.019620.PubMedPubMed CentralGoogle Scholar
- Neder JA, Fuld JP, Overend T, Thirlwell J, Carter R, Stevenson R, Ward SA: Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med. 2007, 101: 2056-64. 10.1016/j.rmed.2007.06.006.PubMedGoogle Scholar
- O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004, 24: 86-94. 10.1183/09031936.04.00072703.PubMedGoogle Scholar
- Casaburi R: Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005, 2: 1-5. 10.1081/COPD-200050576.PubMedGoogle Scholar
- Akkoca Yildiz O, Onen ZP, Demir G, Eriş Gülbay B, Saryal S, Karabiyikoğlu G: Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?. Tuberk Toraks. 2006, 54: 105-13.PubMedGoogle Scholar
- Ayers ML, Mejia R, Ward J, Lentine T, Mahler DA: Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J. 2001, 17: 1132-7. 10.1183/09031936.01.00088801.PubMedGoogle Scholar
- Patakas D, Andreadis D, Mavrofridis E, Argyropoulou P: Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med. 1998, 92: 1116-21. 10.1016/S0954-6111(98)90404-8.PubMedGoogle Scholar
- Jones PW, Bosh TK: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997, 155: 1283-89.PubMedGoogle Scholar
- Jones PW: St. George's Respiratory Questionnaire: MCID. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005, 2: 75-9. 10.1081/COPD-200050513.PubMedGoogle Scholar
- Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R: Safety of long-acting β-agonists in stable COPD. Chest. 2008, 133: 1079-87. 10.1378/chest.07-1167.PubMedGoogle Scholar
- Sapey E, Stockley R: COPD exacerbations · 2: Aetiology. Thorax. 2006, 61: 250-8. 10.1136/thx.2005.041822.PubMedPubMed CentralGoogle Scholar
- Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Löfdahl CG: COPD exacerbations: the importance of a standard definition. Respir Med. 2004, 98: 99-107. 10.1016/j.rmed.2003.09.001.PubMedGoogle Scholar
- Keene ON, Calverley PMA, Jones PW, Vestbo J, Anderson JA: Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J. 2008, 32: 17-24. 10.1183/09031936.00161507.PubMedGoogle Scholar
- Liu D, Menjoge S: Statistical analysis of COPD exacerbations (letter). Eur Respir J. 2008, 32: 1422-10.1183/09031936.00124108.PubMedGoogle Scholar
- Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UF, Silkoff PE: One-year evaluation of the efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease. Drugs. 2009, 69: 549-65. 10.2165/00003495-200969050-00004.PubMedPubMed CentralGoogle Scholar
- Baker Wl, Baker EL, Coleman CI: Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed treatment comparison meta-analysis. Pharmacotherapy. 2009, 29: 891-905. 10.1592/phco.29.8.891.PubMedGoogle Scholar
- Calverley PM: Long-acting inhaled bronchodilators in COPD: how many drugs do we need?. Eur Respir J. 2005, 26: 190-1. 10.1183/09031936.05.00054905.PubMedGoogle Scholar
- Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group: The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006, 129: 15-26. 10.1378/chest.129.1.15.PubMedGoogle Scholar
- Drazen JM, O'Byrne PM: Risks of long-acting beta-agonists in achieving asthma control. New Eng J Med. 2009, 360: 1671-2. 10.1056/NEJMe0902057.PubMedGoogle Scholar
- Sears MR: Safety of long-acting β-agonists. Are new data really required?. Chest. 2009, 136: 604-6. 10.1378/chest.09-1214.PubMedGoogle Scholar
- Guerra S: Overlap of asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2005, 11: 7-13.PubMedGoogle Scholar
- Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DM, Dalal A, Scharf SM: Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008, 134: 14-9. 10.1378/chest.07-2317.PubMedGoogle Scholar
- Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. 2009, [http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1561]Google Scholar
- Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ, et al: The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999, 115: 966-71. 10.1378/chest.115.4.966.PubMedGoogle Scholar
- Donohue JF: Therapeutic responses in asthma and COPD. Bronchodilators. Chest. 2004, 126 (2 Suppl): 125S-137S. 10.1378/chest.126.2_suppl_1.125S.PubMedGoogle Scholar
- Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S: Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008, 31: 742-50. 10.1183/09031936.00129607.PubMedGoogle Scholar
- Salpeter SR, Buckley NS, Salpeter EE: Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006, 21: 1011-19. 10.1111/j.1525-1497.2006.00507.x.PubMedPubMed CentralGoogle Scholar
- La Vecchia C, Fabbri LM: Prevention of death in COPD (letter). New Engl J Med. 2007, 356: 2211-2. 10.1056/NEJMc070783.PubMedGoogle Scholar
- Suissa S, Ernst P, Vandemheen KL, Aaron SD: Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008, 31: 927-33. 10.1183/09031936.00098307.PubMedGoogle Scholar
- Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG: Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998, 114: 411-5. 10.1378/chest.114.2.411.PubMedGoogle Scholar
- Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW: Heart failure and chronic obstructive pulmonary disease: an ignored combination?. Eur J Heart Fail. 2006, 8: 706-11. 10.1016/j.ejheart.2006.01.010.PubMedGoogle Scholar
- Hawkins NM, Wang D, Petrie M, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Stergren JO, Michelson EL, Pocock SJ, Maggioni AP, McMurray JJV, for the CHARM investigators and committees: Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010,Google Scholar
- Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010,Google Scholar
- Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, Macintyre K, McMurray JJ: Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail. 2010, 12: 17-24. 10.1093/eurjhf/hfp160.PubMedGoogle Scholar
- Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV: Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009, 11: 130-9. 10.1093/eurjhf/hfn013.PubMedPubMed CentralGoogle Scholar
- Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD: Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003, 123: 1964-9. 10.1378/chest.123.6.1964.PubMedGoogle Scholar
- Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD: Association between chronic heart failure and inhaled β-2-adrenoceptor agonist. Am Heart J. 2004, 148 (5): 915-20. 10.1016/j.ahj.2004.03.048.PubMedGoogle Scholar
- Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA: Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2007, 20: 571-9. 10.1016/j.pupt.2006.06.003.PubMedGoogle Scholar
- Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C: Cardiovascular safety of salmeterol in COPD. Chest. 2003, 123: 1817-24. 10.1378/chest.123.6.1817.PubMedGoogle Scholar
- Randell J, Saarinen A, Walamies M, Vahteristo M, Silvasti M, Lähelmä S: Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer. Respir Med. 2005, 99: 1485-93. 10.1016/j.rmed.2005.08.023.PubMedGoogle Scholar
- Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K: Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008, 2: 199-208. 10.1177/1753465808093934.PubMedGoogle Scholar
- Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ, Morganroth J: Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008, 87: 319-28. 10.1097/MD.0b013e31818fcc02.Google Scholar
- Vincken W, van Noord JA, Greefhorst APM, Bantje ThA, Kesten S, Korducki L, Cornelissen PJG: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002, 19: 209-16. 10.1183/09031936.02.00238702.PubMedGoogle Scholar
- Breekveldt-Postmaa NS, Koerselman J, Erkens JA, Lammers J-WJ, Herings RMC: Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007, 101: 1398-405. 10.1016/j.rmed.2007.01.025.Google Scholar
- Bourbeau J, Bartlett SJ: Patient adherence in COPD. Thorax. 2008, 63: 831-8. 10.1136/thx.2007.086041.PubMedGoogle Scholar
- Cote C, Pearle J, Sharafkhaneh A, Spangenthal S: Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009, 22: 44-9. 10.1016/j.pupt.2008.11.010.PubMedGoogle Scholar
- Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T: Development and validation of the Capacity of Daily Living during the Morning and Global Chest Symptoms Questionnaires in COPD. Eur Respir J. 2010, 36: 96-104. 10.1183/09031936.00123709.PubMedGoogle Scholar
- Janssens W, Van den Brande P, Hardeman E, De Langhe E, Philps T, Troosters T, Decramer M: Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008, 31: 78-83. 10.1183/09031936.00024807.PubMedGoogle Scholar
- Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H: Comparison if the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005, 18: 273-82. 10.1089/jam.2005.18.273.PubMedGoogle Scholar
- Cazzola M, Matera MG, Lötvall J: Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005, 14: 775-83. 10.1517/13543718.104.22.1685.PubMedGoogle Scholar
- Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT study investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 1543-54. 10.1056/NEJMoa0805800.PubMedGoogle Scholar
- Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M, on behalf of the UPLIFT investigators: Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010, 36: 65-73. 10.1183/09031936.00127809.PubMedGoogle Scholar
- Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L, Turner RJ, Trifilieff A: In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006, 317: 762-70. 10.1124/jpet.105.098251.PubMedGoogle Scholar
- Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M: 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin. 2009, 25: 463-70. 10.1185/03007990802675096.PubMedGoogle Scholar
- Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M: Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007, 20: 740-9. 10.1016/j.pupt.2006.09.001.PubMedGoogle Scholar
- Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S: Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009, 22: 492-6. 10.1016/j.pupt.2009.05.001.PubMedGoogle Scholar
- Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting â2-agonist, on isolated human bronchi. Eur Respir J. 2007, 29: 575-81. 10.1183/09031936.00032806.PubMedGoogle Scholar
- Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ: Pharmacological characterisation of indacaterol a novel once daily inhaled β2 adrenoceptor agonist, on small airways in human and rat precision cut lung slices. J Pharmacol Exp Ther. 2008, 324: 270-5. 10.1124/jpet.107.129296.PubMedGoogle Scholar
- Lombardi D, Cuenoud B, Krämer SD: Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacology properties?. Eur J Pharm Sci. 2009, 38: 533-47. 10.1016/j.ejps.2009.10.001.PubMedGoogle Scholar
- Pontier SM, Percherancier Y, Galandrin S, Breit A, Gale C, Bouvier M: Cholesterol-dependent separation of the β2-adrenergic receptor from its partners determines signalling efficacy. Insight into nanoscale organization of signal transduction. J Biol Chem. 2008, 283: 24659-72. 10.1074/jbc.M800778200.PubMedPubMed CentralGoogle Scholar
- ClinicalTrials.gov: 2010, [http://www.clinicaltrials.gov]
- Feldman G, Siler T, Pasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B, for the INLIGHT 1 Study Group: Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulmonary Medicine. 2010, 10: 11-10.1186/1471-2466-10-11.PubMedPubMed CentralGoogle Scholar
- Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D: Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010, 23: 165-171. 10.1016/j.pupt.2010.01.003.PubMedGoogle Scholar
- Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioğlu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, for the INHANCE study investigators: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010, 182: 155-162. 10.1164/rccm.200910-1500OC.PubMedGoogle Scholar
- Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B: Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2010,Google Scholar
- Rennard SI, Chapman KR, Luthra A, Swales J, Lassen C, Owen R, Kramer B: Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease [abstract]. Chest. 2009, 136: 4S-f.Google Scholar
- Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A: Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010, 334: 53-62. 10.1124/jpet.110.167007.PubMedGoogle Scholar
- Bouyssou T, Hoenke C, Rudolf K, Lustenberger P, Pestel S, Sieger P, Lotz R, Heine C, Büttner FH, Schnapp A, Konetzki I: Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010, 20: 1410-4. 10.1016/j.bmcl.2009.12.087.PubMedGoogle Scholar
- Kanniess F, Make BJ, Petruzzelli S: Acute effect of carmoterol, a long-acting beta2-agonist, in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008, 177 (Abstracts): A655-Google Scholar
- Make BJ, Kanniess F, Bateman ED, Linberg SE: Efficacy of 3 different doses of carmoterol, a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008, 177 (Abstracts): A961-Google Scholar
- Rossing TH, Make BJ, Heyman ER: Carmoterol does not induce tolerance in COPD [abstract]. Am J Respir Crit Care Med. 2008, 177 (Abstracts): A962-Google Scholar
- Tashkin DP, Kleerup EC, Heyman ER, Norris D, Tetruzzelli S: Effect of carmoterol pMDI on 24-hour FEV1 in COPD patients [abstract]. Eur Respir J. 2009, 34 (Suppl 53): E4346-Google Scholar
- Linberg SE, Heyman ER, Nandeuil MA, Kottakis I, Maison-Blance P: Cardiac safety of the novel very long-acting beta2-agonist carmoterol following single rising doses in healthy volunteers [abstract]. Eur Respir J. 2006, 28 (Suppl 50): 665s-Google Scholar
- Bateman ED, Make BJ, Nandeuil MA: Safety and tolerability of a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008, 177 (Abstracts): A653-Google Scholar
- Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Box PC, Butchers PR, Coe DM, Conroy R, Emmons A, Ford AJ, Holmes DS, Horsley H, Kerr F, Li-Kwai-Cheung AM, Looker BE, Mann IS, McLay IM, Morrison VS, Mutch PJ, Smith CE, Tomlin P: Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010, 53 (11): 4522-30. 10.1021/jm100326d.PubMedGoogle Scholar
- Theravance, inc: [Accessed October 2009], [http://www.theravance.com]
- Macintyre F, Jones I, Surujbally B: A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a β2 adrenoreceptor agonist, PF-00610355 [abstract]. Eur Respir J. 2009, 34 (Suppl 53): P2017-Google Scholar
- Li GL, MacIntyre F, Surujbally B, Chong CL, Davis J: Safety and toleration of PF-00610355, a novel inhaled long acting β2 adrenoreceptor agonist [abstract]. Eur Respir J. 2009, 34 (Suppl 53): P2017-Google Scholar
- Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K: Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial. Respir Med. 2008, 102: 479-87. 10.1016/j.rmed.2007.12.019.PubMedGoogle Scholar
- Tashkin D, Pearle J, Iezzoni D, Verghese ST: Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease: findings from a randomized, placebo-controlled trial. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2009, 6: 17-25. 10.1080/15412550902724073.PubMedGoogle Scholar
- Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT: Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med. 2009, 103: 516-24. 10.1016/j.rmed.2008.12.014.PubMedGoogle Scholar
- van Noord JA, Aumann JL, Janssens E, Smeets JJ, Mueller A, Cornelissen P: Combination therapy of tiotropium plus salmeterol superior to single agent therapy in terms of dyspnea improvement in COPD [abstract]. Chest. 2005, 128: 177S-Google Scholar
- Rabe KF, Timmer W, Sagkriotis A, Viel K: Comparison of a combination of tiotropium plus formoterol plus fluticasone in moderate COPD. Chest. 2008, 134: 255-62. 10.1378/chest.07-2138.PubMedGoogle Scholar
- van Noord JA, Buhl R, LaForce C, Martin C, Jones F, Dolker M, Overend T: QVA149, a novel combination of indacaterol and glycoprronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD [abstract]. Eur Respir J. 2009, 34 (Suppl 53): E4347-Google Scholar
- Fabbri LM, van de Maele B, Lemmens B, Martin C, Horton R, Dolker M, Overend T: Cardiovascular safety of QVA149, a novel combination of indacaterol and glycopyrronium compared with indacaterol and placebo in patients with COPD [abstract]. Eur Respir J. 2009, 34 (Suppl 53): P2027-Google Scholar
- Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, Fitzgerald M, for the Canadian Thoracic Society/Canadian Clinical Research Consortium: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007, 146: 545-55.PubMedGoogle Scholar
- Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ: Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008, 63: 592-8. 10.1136/thx.2007.087213.PubMedGoogle Scholar
- Welte T, Miravitlles M, Hernandez P, Erikkson G, Peterson S, Polanowski T, Kessler R: Efficacy and tolerability of budesonide/formoterol added to tiotropium in COPD patients. Am J Respir Crit Care Med. 2009, 180: 741-50. 10.1164/rccm.200904-0492OC.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.